Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUMO2 pseudogene 21 is a non-functional pseudogene related to the *SUMO2* gene, which encodes a small ubiquitin-like modifier involved in post-translational modification of proteins. Pseudogenes like SUMO2P21 arise through mutations that disable protein-coding capacity; they generally do not produce functional proteins or play direct biological roles, nor are they considered therapeutic targets[4][3][5]. Numerous SUMO2-related pseudogenes exist in the human genome; these mostly represent genomic "fossils" without clinical significance.\n\nIf you intended to ask about the functional protein SUMO2 (Small ubiquitin-like modifier 2), let me know, as that is a distinct, biologically active protein involved in sumoylation and diverse cellular processes[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUMO2 pseudogene 21 (SUMO2P21).